{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:51:42Z","timestamp":1780091502591,"version":"3.54.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T00:00:00Z","timestamp":1561161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T00:00:00Z","timestamp":1561161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s11883-019-0797-3","type":"journal-article","created":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T08:02:32Z","timestamp":1561190552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project"],"prefix":"10.1007","volume":"21","author":[{"given":"Richard","family":"Ceska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavs","family":"Latkovskis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat V.","family":"Ezhov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Freiberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Lalic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olena","family":"Mitchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyorgy","family":"Paragh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaneta","family":"Petrulioniene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belma","family":"Pojskic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Raslova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandr B.","family":"Shek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branislav","family":"Vohnout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Altschmiedova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Todorovova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,22]]},"reference":[{"key":"797_CR1","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1161\/CIRCULATIONAHA.114.012477","volume":"131","author":"AM Navar-Boggan","year":"2015","unstructured":"Navar-Boggan AM, Peterson ED, D\u2019Agostino RB, et al. Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease. Circulation. 2015;131:451\u20138.","journal-title":"Circulation."},{"key":"797_CR2","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"\u2022\u2022 Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478\u201390 The statement is focused on underdiagnosis, undertreatment, and prevalence of coronary heart disease of FH patients, where screening, diagnostic, and treatment play the major role.","journal-title":"Eur Heart J"},{"key":"797_CR3","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1172\/JCI200318925","volume":"111","author":"DJ Rader","year":"2003","unstructured":"Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest. 2003;111:1795\u2013803.","journal-title":"J Clin Invest"},{"key":"797_CR4","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/humu.21258","volume":"31","author":"R Huijgen","year":"2010","unstructured":"\u2022 Huijgen R, Kindt I, Fouchier SW, et al. Functionality of sequence variants in the genes coding for the low-density lipoprotein receptor and apolipoprotein B in individuals with inherited hypercholesterolemia. Hum Mutat. 2010;31:752\u201360 Detection of pathogenic variants of LDLR and APOB gene mutations of FH patients is based on specified criteria.","journal-title":"Hum Mutat"},{"key":"797_CR5","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0140-6736(12)62127-8","volume":"381","author":"PJ Talmud","year":"2013","unstructured":"Talmud PJ, Shah S, Whittall R, Futema M, Howard P, Cooper JA, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet. 2013;381:1293\u2013301.","journal-title":"Lancet."},{"issue":"5","key":"797_CR6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/aje\/kwh236","volume":"160","author":"MA Austin","year":"2004","unstructured":"Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol. 2004;160(5):407\u201320.","journal-title":"Am J Epidemiol"},{"key":"797_CR7","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1046\/j.1365-2362.2001.00915.x","volume":"31","author":"OS Descamps","year":"2001","unstructured":"Descamps OS, Gilbeau JP, Leysen X, van Leuven F, Heller FR. Impact of genetic defects on atherosclerosis in patients suspected of familial hypercholesterolaemia. Eur J Clin Investig. 2001;31:958\u201365.","journal-title":"Eur J Clin Investig"},{"key":"797_CR8","first-page":"26","volume":"11","author":"TP Leren","year":"2008","unstructured":"Leren TP, Finborud TH, Manshaus TE, et al. Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. Community Genet. 2008;11:26\u201335.","journal-title":"Community Genet"},{"key":"797_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2013.12.020","volume":"233","author":"J Besseling","year":"2014","unstructured":"Besseling J, Kindt I, Hof M, Kastelein JJP, Hutten BA, Hovingh GK. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers. Atherosclerosis. 2014;233:219\u201323.","journal-title":"Atherosclerosis."},{"key":"797_CR10","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, Chapman MJ, Ray K, Bor\u00e9n J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844\u201353.","journal-title":"Eur Heart J"},{"key":"797_CR11","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.1365-2796.2004.01405.x","volume":"256","author":"AC Jansen","year":"2004","unstructured":"Jansen AC, van Aalst-Cohen ES, Tanck MW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med. 2004;256:482\u201390.","journal-title":"J Intern Med"},{"key":"797_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.atherosclerosis.2010.10.008","volume":"214","author":"C Masoura","year":"2011","unstructured":"Masoura C, Pitsavos C, Aznaouridis K, Skoumas I, Vlachopoulos C, Stefanadis C. Arterial endothelial function and wall thickness in familial hypercholesterolemia and familial combined hyperlipidemia and the effect of statins. A systematic review and meta-analysis. Atherosclerosis. 2011;214:129\u201338.","journal-title":"Atherosclerosis."},{"issue":"3 Suppl","key":"797_CR13","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/j.jacl.2011.03.451","volume":"5","author":"JG Robinson","year":"2011","unstructured":"Robinson JG, Goldberg AC. National Lipid Association Expert Panel on familial hypercholesterolemia. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3 Suppl):S18\u201329.","journal-title":"J Clin Lipidol"},{"key":"797_CR14","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jacl.2014.05.008","volume":"8","author":"Z Ademi","year":"2014","unstructured":"Ademi Z, Watts GF, Pang J, Sijbrands EJG, van Bockxmeer FM, O'Leary P, et al. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. J Clin Lipidol. 2014;8:390\u2013400.","journal-title":"J Clin Lipidol."},{"key":"797_CR15","doi-asserted-by":"publisher","first-page":"a2423","DOI":"10.1136\/bmj.a2423","volume":"337","author":"J Versmissen","year":"2008","unstructured":"Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DCG, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423.","journal-title":"BMJ."},{"key":"797_CR16","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","volume":"124","author":"FJ Raal","year":"2011","unstructured":"Raal FJ, Pilcher GJ, Panz VR, van Deventer HE, Brice BC, Blom DJ, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011;124:2202\u20137.","journal-title":"Circulation."},{"issue":"10","key":"797_CR17","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/S0002-9149(02)02774-1","volume":"90","author":"C Gagn\u00e9","year":"2002","unstructured":"Gagn\u00e9 C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002;90(10):1084\u201391.","journal-title":"Am J Cardiol"},{"issue":"5","key":"797_CR18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.4065\/80.5.587","volume":"80","author":"TA Pearson","year":"2005","unstructured":"Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP IIIgoals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc. 2005;80(5):587\u201395.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"797_CR19","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jacl.2009.02.004","volume":"3","author":"SH Stephenson","year":"2009","unstructured":"\u2022 Stephenson SH, Larrinaga-Shum S, Hopkins PN. Benefits of the MEDPED treatment support program for patients with familial hypercholesterolemia. J Clin Lipidol. 2009;3(2):94\u2013100 The article reports advantages and disadvantages of the MEDPED program which should improve the achievement of LDL-C target levels of FH patients by appropriate treatment.","journal-title":"J Clin Lipidol"},{"key":"797_CR20","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/1744-1609.12023","volume":"11","author":"E Hammond","year":"2013","unstructured":"Hammond E, Watts GF, Rubinstein Y, Farid W, Livingston M, Knowles JW, et al. Role of international registries in enhancing the care of familial hypercholesterolaemia. Int J Evid Based Healthc. 2013;11:134\u20139.","journal-title":"Int J Evid Based Healthc"},{"issue":"11","key":"797_CR21","first-page":"942","volume":"61","author":"T Freiberger","year":"2015","unstructured":"Freiberger T, Vrabl\u00edk M. Early diagnosis of familial hypercholesterolemia in Czech Republic in pursuance of MedPed project. Vnitr Lek. 2015;61(11):942\u20135.","journal-title":"Vnitr Lek"},{"key":"797_CR22","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1136\/bmj.321.7254.148","volume":"321","author":"HA Neil","year":"2000","unstructured":"Neil HA, Hammond T, Huxley R, Matthews DR, Humphries SE. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ. 2000;321:148.","journal-title":"BMJ."},{"key":"797_CR23","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/CIRCGENETICS.111.962456","volume":"5","author":"R Huijgen","year":"2012","unstructured":"Huijgen R, Hutten BA, Kindt I, Vissers MN, Kastelein JJP. Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26,406 individuals tested for genetic FH. Circ Cardiovasc Genet. 2012;5:354\u20139.","journal-title":"Circ Cardiovasc Genet"},{"key":"797_CR24","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670\u201381.","journal-title":"Lancet."},{"key":"797_CR25","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1146\/annurev-med-022613-090402","volume":"65","author":"EA Stein","year":"2014","unstructured":"Stein EA, Raal F. Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu Rev Med. 2014;65:417\u201331.","journal-title":"Annu Rev Med"},{"key":"797_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2014.05.004","volume":"235","author":"F Raal","year":"2014","unstructured":"Raal F, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, et al. Trial evaluating evolocumab, a PCSK9 antibody, in patients with homozygous FH (TESLA): results of the randomized, double-blind placebo-controlled trial. Atherosclerosis. 2014;235:e12.","journal-title":"Atherosclerosis."},{"issue":"1","key":"797_CR27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.amjcard.2016.09.010","volume":"119","author":"D Gaudet","year":"2017","unstructured":"Gaudet D, Watts GF, Robinson JG, Minini P, Sasiela WJ, Edelberg J, et al. Effect of alirocumab on lipoprotein(a) over \u22651.5 years (from the phase 3 ODYSSEY program). Am J Cardiol. 2017;119(1):40\u20136.","journal-title":"Am J Cardiol"},{"issue":"6","key":"797_CR28","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1194\/jlr.P065334","volume":"57","author":"FJ Raal","year":"2016","unstructured":"Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Blom D, Seidah NG, et al. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. J Lipid Res. 2016;57(6):1086\u201396.","journal-title":"J Lipid Res"},{"issue":"4","key":"797_CR29","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","volume":"137","author":"MP Bonaca","year":"2018","unstructured":"Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation. 2018;137(4):338\u201350.","journal-title":"Circulation."},{"issue":"19","key":"797_CR30","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","volume":"370","author":"DJ Blom","year":"2014","unstructured":"\u2022 Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809\u201319 Treatment of FH patients with monoclonal antibody PCSK9 led to a significant decrease in the lipid levels.","journal-title":"N Engl J Med"},{"issue":"5","key":"797_CR31","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","volume":"168","author":"GG Schwartz","year":"2014","unstructured":"\u2022 Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014;168(5):682\u20139 Treatment of FH patients with monoclonal antibody PCSK9 led to a significant decrease in the lipid levels.","journal-title":"Am Heart J"},{"issue":"11","key":"797_CR32","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","volume":"380","author":"KK Ray","year":"2019","unstructured":"Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022\u201332.","journal-title":"N Engl J Med"},{"issue":"17","key":"797_CR33","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1093\/eurheartj\/ehw028","volume":"37","author":"M Benn","year":"2016","unstructured":"Benn M, Watts GF, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur Heart J. 2016;37(17):1384\u201394.","journal-title":"Eur Heart J"},{"key":"797_CR34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.atherosclerosis.2018.06.011","volume":"277","author":"G Latkovskis","year":"2018","unstructured":"Latkovskis G, Saripo V, Gilis D, Nesterovics G, Upena-Roze A, Erglis A. Latvian registry of familial hypercholesterolemia: the first report of three-year results. Atherosclerosis. 2018;277:347\u201354.","journal-title":"Atherosclerosis."},{"issue":"1","key":"797_CR35","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0021-9258(19)75941-9","volume":"262","author":"MA Lehrman","year":"1987","unstructured":"Lehrman MA, Schneider WJ, Brown MS, et al. The Lebanese allele at the low density lipoprotein receptor locus. Nonsense mutation produces truncated receptor that is retained in endoplasmic reticulum. J Biol Chem. 1987;262(1):401\u201310.","journal-title":"J Biol Chem"},{"issue":"7","key":"797_CR36","doi-asserted-by":"publisher","first-page":"E682","DOI":"10.1002\/humu.21002","volume":"30","author":"M Abifadel","year":"2009","unstructured":"Abifadel M, Rab\u00e8s JP, Jambart S, et al. The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene. Hum Mutat. 2009;30(7):E682\u201391.","journal-title":"Hum Mutat"},{"key":"797_CR37","doi-asserted-by":"publisher","first-page":"891","DOI":"10.5551\/jat.35949","volume":"23","author":"GF Watts","year":"2016","unstructured":"Watts GF, Ding PY, George P, et al. Translational research for improving the care of familial hypercholesterolemia: the \u201cTen Countries Study\u201d and beyond. J Atheroscler Thromb. 2016;23:891\u2013900.","journal-title":"J Atheroscler Thromb"},{"key":"797_CR38","doi-asserted-by":"publisher","first-page":"e017817","DOI":"10.1136\/bmjopen-2017-017817","volume":"7","author":"J Pang","year":"2017","unstructured":"Pang J, Hu M, Lin J, Miida T, Nawawi HM, Park JE, et al. An enquiry based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the Asia-Pacific region: the \u201cTen Countries Study\u201d. BMJ Open. 2017;7:e017817.","journal-title":"BMJ Open"},{"key":"797_CR39","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.atherosclerosis.2018.08.051","volume":"277","author":"EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) Investigators","year":"2018","unstructured":"EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) Investigators. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis. 2018;277:234\u201355.","journal-title":"Atherosclerosis."}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-019-0797-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-019-0797-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-019-0797-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T08:14:34Z","timestamp":1610007274000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-019-0797-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,22]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["797"],"URL":"https:\/\/doi.org\/10.1007\/s11883-019-0797-3","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,22]]},"assertion":[{"value":"22 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Katarina Lalic, Olena Mitchenko, Zaneta Petrulioniene, Belma Pojskic, Aleksandr B. Shek, Tereza Altschmiedova, and Veronika Todorovova declare no conflicts of interest. Richard Ceska has been a consultant to Akcea Therapeutics, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Egis, MSD, NovoNordisk, Sanofi and board member of Amgen, Herbacos Recordati, Mylan, Novartis, Novatin, Pfizer, Promed, Roche, Sanofi, Servier, and he is paid speaker to Akcea Therapeutics, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Egis, Herbacos Recordati, MSD, Mylan, Novartis, Novatin, NovoNordisk, Pfizer, Promed, Roche, Sanofi, and Servier. Richard Ceska has received honoraria from Amgen, Esperion, Kowa, Regeneron, and Sanofi (PI, NC), and he reports grant support from IAS, Pfizer, and Teva. Gustavs Latkovskis declares speaker fees, honoraria, consultancy, and board membership to Astra Zeneca, Bayer, Berlin Chemie AG, Boehringer-Ingelheim, Servier, Mylan, Sanofi Aventis, Amgen, Novo-Nordisk, Krka Pharma, Roche Diagnostics, and Novartis, and he reports grant support from Latvian Council of Science. Marat V. Ezhov is a paid speaker from Amgen, Alexion, AZ, Berlin Chemie, Egis, KRKA, NovoNordisk, Pfizer, Recordati, and Sanofi, and he also reports travel fees. Tomas Freiberger has received honoraria from Amgen and Sanofi and grants from AZV, Ministry of Health, and CR for his institution, and he has been a consultant to Sanofi. Gyorgy Paragh has been a consultant and he declares travel fees from Richter Gedeon, fees for board membership from Sanofi Aventis and Amgen, and honoraria, and he is also a paid speaker. Katarina Raslova has received financial support from Sanofi, Amgen, NovoNordisk, and Mylan for consultancy, board membership, honoraria, and travel fees, and she also reports grant support from Sanofi for her institution. Branislav Vohnout has been a consultant to Sanofi, and he has received honoraria from Amgen, Sanofi, Mylan, Krka, and NovoNordisk. Branislav Vohnout has also received support from Amgen, Sanofi for board membership, and from Sanofi, Mylan, Amgen for traveling, and he is a paid speaker by Sanofi and Mylan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The leaders in all countries involved in the ScreenPro FH project got acquainted with ethical statements of the country, and the project complies with ethical criteria of a non-interventional retrospective study in all participating countries.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"36"}}